8-K: bioAffinity Technologies Reports Over 100% Sales Growth

bioAffinity Technologies announced over 100% sales growth for its CyPath Lung test through Q3 2026, driven by increased clinical adoption and physician utilization.

Summary

• bioAffinity Technologies reported a more than 100% increase in sales for its CyPath Lung test through the third quarter of 2026 compared to the same period in 2025.
• The number of physicians ordering the CyPath Lung test increased by 89% in Q3 2026 compared to Q3 2025.
• Physicians who previously used the test increased their utilization by 48% year-over-year.
• A total of over 1,620 tests were delivered through Q3 2026, compared to 775 tests through Q3 2025.
• The company is focused on expanding access and adoption, particularly through a new distribution agreement with AvMEDICAL.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, indicating strong market acceptance and growth for the company's core product.

Positives

• Sales of CyPath Lung test increased by more than 100% through Q3 2026 compared to 2025.
• The number of ordering physicians grew by 89% in Q3 2026 versus Q3 2025.
• Existing physician users increased their utilization of CyPath Lung by 48% year-over-year.
• Over 1,620 tests were delivered through Q3 2026, a significant increase from 775 tests in Q3 2025.
• The company is actively pursuing growth strategies, including a new distribution agreement with AvMEDICAL to expand reach within the government healthcare system.

Negatives

• The company acknowledges the need for additional capital and its ability to obtain financing on acceptable terms, or at all, as a risk factor.

Risks

• Competition from other diagnostic technologies and companies.
• The company's ability to maintain and expand adoption of CyPath Lung as a Laboratory Developed Test.
• Compliance with evolving CLIA and FDA regulatory requirements applicable to laboratory developed tests.
• The company's need for additional capital and its ability to obtain financing on acceptable terms, or at all.

Future Outlook

The company believes it is well-positioned to pursue similar results generated by a larger base of physician prescribers and is focused on executing its new distribution agreement with AvMEDICAL, which is expected to broaden its reach in the government healthcare system. The company anticipates continued growth in sales and physician adoption of CyPath Lung.

Management Comments

• "One of our objectives for 2026 is executing on our strategy to expand access and drive adoption of CyPath Lung with physicians who have used our test over time. We believe that sales of CyPath Lung in the third quarter of this year demonstrate the ongoing success of our efforts."
• "As clinicians, we are happy to see more eligible patients undergoing the recommended lung cancer screening. But as more nodules are identified by imaging, physicians increasingly need more information to help determine the appropriate next steps for individual patients."
• "CyPath Lung is designed to help fill that need by providing a result indicating either likely or unlikely malignancy in the lung, which can be considered alongside imaging, clinical history and other findings to help determine whether a patient is most likely to benefit from additional monitoring, further diagnostic evaluation or an invasive procedure."

Industry Context

StockSavvy.ai notes that the strong growth in CyPath Lung sales aligns with the increasing demand for noninvasive diagnostic tools in oncology and the broader trend of leveraging AI and advanced diagnostics for early disease detection.

Stakeholder Impact

• Shareholders: Positive impact due to strong sales growth and market adoption of the company's core product.
• Physicians: Increased availability and utilization of a noninvasive tool for lung cancer assessment.
• Patients: Potential for earlier and more accurate lung cancer detection, leading to better treatment outcomes.

Next Steps

• Continue to expand access and drive adoption of CyPath Lung with physicians.
• Execute the new distribution agreement with AvMEDICAL to broaden reach in the government healthcare system.
• Increase marketing efforts to pursue similar results generated by a larger base of physician prescribers.

Key Dates

Recommendation

The strong sales growth is a positive indicator, but the company's reliance on future financing and competition in the diagnostic space warrant a cautious approach. Holding allows investors to monitor further execution and market penetration.

Keywords

CyPath Lung, lung cancer detection, noninvasive test, flow cytometry, AI, biotechnology, clinical adoption, early detection